Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced today that its subsidiary, Innovotech Labs Corporation, will receive advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.
The new testing methods are designed to align with evolving international regulatory standards and address medical device manufacturers' needs in areas including proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development initiated last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are increasingly requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand Innovotech's service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
The funding comes at a critical time when medical device manufacturers face increasing scrutiny from regulators such as the U.S. Food and Drug Administration and Health Canada. Enhanced antimicrobial testing can help companies prove that their products reduce infection risks, a key factor in gaining market approval and adoption. For the healthcare industry, this translates to safer devices and potentially fewer hospital-acquired infections, which are a major cause of patient complications and healthcare costs.
Innovotech is a recognized leader in biofilm science and antimicrobial testing, operating through ISO-certified and GMP-accredited laboratories. The company's proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. With this new support, Innovotech aims to deepen its technical capabilities and offer higher-complexity testing services that meet rising client demand. The company serves clients across multiple sectors and geographies, providing reliable, decision-enabling data aligned with regulatory expectations.
The implications for the industry are significant. As antimicrobial resistance grows and regulatory standards tighten, medical device manufacturers need more sophisticated testing to validate their products. Innovotech's enhanced services could become a critical resource for companies navigating these challenges, potentially accelerating time-to-market for new devices and improving patient outcomes. For leaders in business and technology, this development underscores the importance of investing in specialized testing infrastructure to maintain competitive advantage in regulated markets.
